LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report
by
Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M.
Lev Hasharon Mental Health Medical Center,
Pardessya, POB 90000, Netanya, 42100, Israel.
lerneram@internet-zahav.net
Isr J Psychiatry Relat Sci 2002;39(2):100-

ABSTRACT

We would like to present the case of a patient who had a prior history of cannabis, ecstasy (MDMA) and LSD abuse and who developed both Hallucinogen Persisting Perception Disorder (HPPD) and a major depressive episode. Following two unsuccessful SSRIs trials, reboxetine was prescribed. During a six-month follow-up period on reboxetine 6 mg./day, no exacerbation of the visual disturbance or recurrence of the depressive features were reported. Reboxetine may have an alpha 2 adrenoreceptor modulating effect on both noradrenaline and serotonin release, thus reboxetine's alpha 2 adrenoreceptor modulating effect on noradrenaline release may affect sympathetic activity and be involved in the recovery process.

LSD
Efficacy
Reboxetine
NARIs versus SSRIs
Reboxetine v fluoxetine
Reboxetine: product info
Reboxetine and the elderly
Reboxtine versus fluoxetine (Prozac)
Reboxetine and the alpha2-adrenergic/5-HT1a receptors

Refs
HOME
HedWeb
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family